Randomized clinical trial comparing fixed-time split dosing and split dosing of oral Picosulfate regimen for bowel preparation

Table 1 Patients characteristics

	Group A ( fixed time split dose preparation) n = 99	Group B (split dose preparation) n = 105	P value
Male: Female	61:38	57:48	NS
Mean age, r	54.6 ± 11.5	54.3 ± 9.4	NS
Age ≥ 65	20 (20.2)	16 (15.2)	NS
Weight (kg)	64.7 ± 11.7	65.4 ± 11.3	NS
BMI (kg/m2)	23.8 ± 3.05	24.2 ± 2.88	NS
BMI ≥ 30	4 (4)	4 (3.8)	NS
History of abdominal surgery	7 (7.1)	7 (6.7)	NS
History of Diabetus mellitus	8 (8.1)	12 (11.4)	NS

NS: Nonspecific.

Table 2 Results of bowel cleansing and adverse effects

	Group A (fixed time split dose preparation) n = 99	Group B (split dose preparation) n = 105	P value
Mean total Ottawa preparation score1	2.57 ± 1.91	2.80 ± 2.51	0.457
Age ≥ 65	3.40 ± 2.03	3.38 ± 2.98	0.976
Right colon, mean (0-4)	0.92 ± 0.71	0.96 ± 0.82	0.692
Mid colon, mean (0-4)	0.76 ± 0.74	0.76 ± 0.83	0.969
Rectosigmoid colon, mean (0-4)	0.73 ± 0.68	0.74 ± 0.85	0.886
Residual fluid, mean (0-2)	0.17 ± 0.43	0.33 ± 0.56	0.023
Adverse GI symptoms, n (%)
Nausea	21 (21.2)	14 (13.3)	0.136
Vomiting	7 (7.1)	3 (2.9)	0.164
Sleep disturbance	2 (2)	0 (0)	0.143
Abdominal discomfort	7 (7.1)	5 (4.8)	0.484
Dizziness	1 (1)	5 (4.8)	0.113
Cold sweating	1 (1)	0 (0)	0.302
Palpitation	0 (0)	1 (1)	0.330
Mean cecal intubation time, min ± SD	5.02 ± 3.42	4.70 ± 2.27	0.428
Physician's satisfaction of inspection	8.17 ± 1.21	8.04 ± 1.51	0.489

¹With the Ottawa bowel preparation scale, lower scores indicate better preparation.

Table 3 Comparison of Ottawa Score between the fixed time split dose (group A) and split dose (group B) preparation

	Group A (fixed time split dose preparation) n = 99	Group B (split dose preparation) n = 105	P value
Sodium picosulfate
2 sachets	2.43 ± 1.90 (n = 67)	3.00 ± 2.68 (n = 70)	0.158
3 sachets	2.84 ± 1.95 (n = 32)	2.40 ± 2.10 (n = 35)	0.375
2 or 3 sachets	2.57 ± 1.91 (n = 99)	2.80 ± 2.51 (n = 105)	0.457